Biologics
Icosagen, EPOK Advance Novel Antibody Therapy for Chronic Kidney Disease-Related Anaemia
Icosagen, a private European protein therapeutics CRDMO, and EPOK Therapeutics Inc., a pre-clinical-stage biopharmaceutical company, based in Toronto, Cana...
September 15, 2026 | News
IonOpticks Launches Aurora Series 5 to Boost Robustness in High-Throughput Proteomics
New CoreJet™ integrated emitter technology and a redesigned nanoZero® union combine proven Aurora Series® performance with a step-change in r...
September 15, 2026 | News
Kelun-Biotech’s Trastuzumab Botidotin Cuts Progression Risk by 61% in Phase III Breast Cancer Study
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or "the Company", 6990.HK) announced that results from the phase III registrational...
September 15, 2026 | News
Accro Bioscience’s AC-101 Enters China’s Rare Disease Innovative Drug Pilot Programme for Blau Syndrome
Accro Bioscience announced that AC-101 tablets have been included in the Rare Diseases Innovative Drug Development Encouragement Pilot Program (the "Caring...
September 15, 2026 | News
TenNor’s TNP-2092 Shows 100% Treatment Success in Early, Acute PJI Phase IIa Trial
TenNor Therapeutics, a near-commercial-stage biotechnology company, announced positive topline results from a Phase IIa proof-of-concept (POC) trial of rif...
September 14, 2026 | News
Transcenta Licenses HiCB Bioprocessing Technology to WuXi Biologics in Strategic Collaboration
Transcenta Therapeutics (HKEX: 06628), a global clinical-stage biopharmaceutical company with fully integrated capabilities in discovery, R&D and proce...
September 11, 2026 | News
CordenPharma Invests €80M to Expand Sterile Injectable Manufacturing Capacity in Italy
CordenPharma accelerates sterile injectable CDMO manufacturing expansion with €80 million multi-year investment in new facility and additional as...
September 11, 2026 | News
Solstice Oncology Launches with $225M Series A to Advance Harbour BioMed’s Porustobart
Porustobart, a second-generation Fc-enhanced CTLA-4 antibody, is being advanced across two clinical indications in the neoadjuvant setting, beginning...
September 11, 2026 | News
Kazia Doses First Patient in Phase II Study of Paxalisib Combination for Aggressive Paediatric Brain Cancer
Multicenter study to evaluate paxalisib plus gemcitabine for children and young adults with recurrent or progressive AT/RT, where no approved therapies cur...
September 11, 2026 | News
Accro, Fosun Pharma Secure China Nod for Phase II/III Trial of AC-201 in Vitiligo
Accro Bioscience (Suzhou) Limited ("Accro") today announced that Shanghai Fosun Pharmaceutical Industrial Development Company Limited ("Fosun Pharma Indust...
September 10, 2026 | News
CelluPro Becomes First Chinese Cell Culture Media Supplier to Secure EXCiPACT GMP Certification
CelluPro, a biotechnology company specializing in serum-free cell culture media and bioprocess solutions, has achieved EXCiPACT™ GMP Certif...
September 09, 2026 | News
CorrectSequence’s Base-Editing Therapy Shows Durable Response Across Diverse β-Hemoglobinopathy Patients
Following 100% transfusion independence in Chinese TDT patients, new study confirms tBE is equally safe and effective for African SCD patients and TDT pati...
September 09, 2026 | News
HORIEN Secures Thai FDA Class 4 Approvals for Three Regenerative Medical Devices
Market-entry initiative targets qualified Thai distributors across dental, surgical, wound-care, and regenerative medicine channels, while solidifying glob...
September 09, 2026 | News
Rznomics Advances High-Efficiency Circular RNA Production with Engineered STS Technology
Rznomics Inc.(KOSDAQ: 476830), a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced a major breakthrough in t...
September 08, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
